VosoritideC-type natriuretic peptide analogue
Vosoritide acts on a signalling pathway involved in achondroplasia. Its trials concern skeletal growth in children with that condition, not increasing height in healthy children or adults.
What is Vosoritide?
Vosoritide is a C-type natriuretic peptide analogue studied and used in children with achondroplasia. Growth-plate status is central to its treatment context. 1 2
How it works
It acts through natriuretic peptide receptor B, countering FGFR3-related signalling at the growth plate.
Effects studied
Linear growth
Clinical trials assessed annualised growth velocity in children with achondroplasia. 1
Evidence: A childhood growth endpoint; it does not directly establish final adult height or benefit after growth plates close.
What does the evidence show?
Achondroplasia growth trial and product-label lead
A specific growth-plate pathway
Achondroplasia involves excessive activity of the FGFR3 pathway, which limits growth in cartilage growth plates. Vosoritide is a modified C-type natriuretic peptide designed to counter part of that signalling through the NPR-B receptor. It addresses a defined biological problem rather than supplying a general growth hormone.
What the trial measured
The retained randomised study compared annualised growth velocity in children with achondroplasia: how quickly height changed during the study. Adult height, mobility, pain, spinal complications and the child’s experience of treatment are separate outcomes requiring appropriate follow-up. 1
Why open growth plates matter
This mechanism depends on growth plates that are still open. Adult height enhancement is a different proposition and cannot be inferred from a paediatric achondroplasia study. The age range and eligibility criteria of each product assessment should be checked separately before applying its findings to a child.
The daily-life side of treatment
Injection-site effects and blood-pressure changes need to be weighed alongside growth. Families and specialist teams also consider monitoring and treatment burden. The measured skeletal effect is one part of the child’s overall care; it cannot establish that the peptide will make anyone taller. 2
Safety & status
Injection-site reactions and blood-pressure effects are relevant safety considerations. Eligibility and monitoring depend on the medicinal product information. 2
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Can it increase height after growth plates close?
The growth-plate mechanism and childhood evidence do not establish that use.
Is faster growth the same as greater final adult height?
No. Annualised growth velocity is measured over a study interval; final adult height requires longer follow-up. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.